PE20021032A1 - Composicion farmaceutica para uso en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata - Google Patents

Composicion farmaceutica para uso en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata

Info

Publication number
PE20021032A1
PE20021032A1 PE2002000305A PE2002000305A PE20021032A1 PE 20021032 A1 PE20021032 A1 PE 20021032A1 PE 2002000305 A PE2002000305 A PE 2002000305A PE 2002000305 A PE2002000305 A PE 2002000305A PE 20021032 A1 PE20021032 A1 PE 20021032A1
Authority
PE
Peru
Prior art keywords
health
quality
alkyl
prostate cancer
trans
Prior art date
Application number
PE2002000305A
Other languages
English (en)
Inventor
Talat Ashraf
Amitabh Singh
Robert J Padley
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/832,752 external-priority patent/US20030022811A1/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PE20021032A1 publication Critical patent/PE20021032A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE UN ANTAGONISTA DEL RECEPTOR DE ENDOTELINA TAL COMO UN COMPUESTO DE PIRROLIDINA DE FORMULA I-a, DONDE R1 Y R2 SON ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILO, ARILO, HETEROARILO, ALQUILO SUSTITUIDO CON CICLOALQUILO, HALO, ARILO, HETEROARILO, HETEROCICLO, OH, O-ALQUILO; R3 ES R4SO2R5, R4COR5; R4 ES ALQUILO, (CH2)-ALQUENILO, (CH2)ALQUINILO, NR6R7, ENTRE OTROS, R5 ES ENLACE, ALQUILENO, NH-ALQUILENO, N-ALQUIL-ALQUILENO; R6 Y R7 SON H, ALQUILO, (CH2)-ALQUILENO, (CH2)-ALQUINILO, CICLOALQUILO, ARILO, ENTRE OTROS; UTILIZANDO DE 1mg/DIA A 25mg/DIA; EN ASOCIACION CON UN DILUYENTE. SON COMPUESTOS PREFERIDOS ACIDO TRANS,TRANS-2-(4-METOXIFENIL)-4-(1,3-BENZODIOXOL-5-IL)-1-(((N-PROPILAMIN)-CARBONIL)METIL)PIRROLIDIN-3-CARBOXILICO; ACIDO TRANS,TRANS-2-(4-METOXIFENIL)-4-(1,3-BENZODIOXOL-5-IL)-1-(AMINCARBONIL)METIL)PIRROLIDIN-3-CARBOXILICO, (2R,3R,4S)-2-(4-METOXIFENIL)-4-(1,3-BENZODIOXOL-5-IL)-1-(((N,N-DIBUTILAMIN)CARBONIL)METIL)PIRROLIDIN-3-CARBOXILICO, ENTRE OTROS. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DEL CANCER DE PROSTATA
PE2002000305A 2001-04-11 2002-04-11 Composicion farmaceutica para uso en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata PE20021032A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/832,752 US20030022811A1 (en) 2001-04-11 2001-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US11848602A 2002-04-08 2002-04-08

Publications (1)

Publication Number Publication Date
PE20021032A1 true PE20021032A1 (es) 2002-11-12

Family

ID=26816420

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000305A PE20021032A1 (es) 2001-04-11 2002-04-11 Composicion farmaceutica para uso en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata

Country Status (10)

Country Link
EP (1) EP1379238A1 (es)
JP (1) JP2005503339A (es)
CN (1) CN1514727A (es)
AR (1) AR033465A1 (es)
BR (1) BR0205970A (es)
CA (1) CA2442591A1 (es)
IL (1) IL158071A0 (es)
MX (1) MXPA03009277A (es)
PE (1) PE20021032A1 (es)
WO (1) WO2002085351A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
WO2007133796A2 (en) * 2006-05-15 2007-11-22 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
JP2010536880A (ja) 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法
CN117751099A (zh) * 2021-08-05 2024-03-22 中国药科大学 酰胺类化合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1301264A (zh) * 1997-08-04 2001-06-27 艾博特公司 内皮素拮抗剂

Also Published As

Publication number Publication date
BR0205970A (pt) 2003-09-30
MXPA03009277A (es) 2004-03-10
CA2442591A1 (en) 2002-10-31
EP1379238A1 (en) 2004-01-14
WO2002085351A1 (en) 2002-10-31
JP2005503339A (ja) 2005-02-03
IL158071A0 (en) 2004-03-28
CN1514727A (zh) 2004-07-21
AR033465A1 (es) 2003-12-17

Similar Documents

Publication Publication Date Title
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
UY27939A1 (es) Compuestos
MXPA03006841A (es) 4-fluoro-n-indan-2-il-benzamida y su uso como producto farmaceutico.
RU2013111077A (ru) Дипептидное пролекарство, его применение и лекарственное средство
PE20070138A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
PE20090772A1 (es) Derivados de bencimidazol
IS8058A (is) Sýklísk súlfónamíð til að hamla gamma seytiasa
RU95113862A (ru) Производные пирролопиримидинов, фармацевтическая композиция, промежуточные соединения
PE20021089A1 (es) Compuestos de triazol como inhibidores de las citoquinas
CY1112689T1 (el) Συνθεση για τη βελτιωση της γνωσης και της μνημης
CY1118924T1 (el) Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας
GB2448255A (en) Compositions and methods relating to treatment of cancer and infectious diseases
PE20211733A1 (es) Amidas de pirrolidina sustituidas
PE20021032A1 (es) Composicion farmaceutica para uso en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata
SE0100569D0 (sv) New compounds
ATE364044T1 (de) 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit
DE602004015603D1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
ATE516366T1 (de) Regulierte aptamer-therapeutika
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
EA200400707A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
PL371746A1 (en) N-substituted3-hydroxy-4-pyridinones and pharmaceuticals containing thereof
SE0403118D0 (sv) New compounds 2
RU2002132883A (ru) Новые полициклические инданилимидазолы, обладающие альфа2 адренергической активностью
GT200000105A (es) Sal difosfato de un derivado de 4" - sustituido - 9 - desoxo - 9a - aza - 9a - homoeritromicina y sucomposicion farmaceutica.
KR910007887A (ko) W-페녹시-헤테로사이클릭 화합물

Legal Events

Date Code Title Description
FA Abandonment or withdrawal